Septodont and Acteon Group acquire Inibsa

Septodont and Acteon Group signed an agreement to acquire Inibsa, a Spanish pharmaceutical laboratory specializing in dental products. Septodont will hold 51% and Acteon Group 49%. Announced November 5, 2024.

“Septodont will be the controlling shareholder of Inibsa, while Acteon Group will be a partner and reference shareholder.”de-pardieu.com

• 2 sources
• de-pardieu.comDe Pardieu advises Acteon Groupon the signing of an agreement with Septodont for the acquisition of Inibsa, phamaceutical laboratory specializing in dental products - De Pardieu Brocas MaffeiJulie OUSSAIDENNov 5, 2024
• iberianlawyer.comDentons advises Septodont on the acquisition of Spanish laboratories Inibsa - Iberian LawyerIlariaNov 25, 2024

Summarized from public sources; check the original articles before acting on it.